It is unknown whether oral fecal microbiota transplants (FMT) can affect the gut microbiota and systemic immunity of HIV-infected individuals.
Thirty ART-treated HIV-infected subjects with a CD4/CD8 ratio <1 were allocated to receive either weekly oral fecal microbiota capsules or placebo for 8 weeks (10 capsules at week 0; 5 capsules/week from weeks 1-7). Three stool donors were selected from a universal donor stool bank based on bacterial abundance of Fecalibacterium and Bacteroides (high) and Prevotella (low) and high fecal butyrate concentrations. We assessed 48-week safety and efficacy, including changes in CD4/CD8 T cells, microbiota engraftment using Illumina 16S rDNA sequencing, T cell activation/senescence, inflammation (sCD14, sCD163, sTNFr-2), bacterial translocation (LTA, LBP) and intestinal damage (FABP2) markers.
Twenty-nine participants, with a mean CD4 count of 641±286 cells/μL completed the 48-week follow-up. FMT was well tolerated, with no grade 3-4 related adverse events. No significant changes were observed in CD4/CD8 T-cells, in T-cell activation/senescence or levels of the inflammation/bacterial translocation markers. Significant between-group differences were observed in FABP2, with higher fold change decrease at week 4 in the FMT arm (0.52 vs. 0.95, p=0.045). Alfa diversity significantly and incrementally increased until week 6 in the FMT arm (FMT vs. placebo arm, p=0.013) and returned to baseline levels at week 48. Unifrac distance trajectories indicated mild engraftment of donor’s microbiota that persisted until week 36 and greater engraftment among the 4 subjects who had received antibiotics in the 12-week period before FMT. LEfSe analyses showed an incremental engraftment of different taxa in the active arm, being Lachnospiraceae family and Faecalibaculum, Faecalicoccus, Fusicatenibacter, Anaerostipes and Ruminococcus genus the taxa more robustly engrafted across time-points.
Repeated oral capsular FMT was safe in HIV-infected subjects on ART and introduced incremental compositional changes in the microbiota. While it is unclear whether this strategy will help to attenuate systemic inflammation, our results indicate that manipulation of the gut microbiota using a non-invasive and safe strategy of FMT delivery is feasible.